Stockwatch: In earnings season, the house always wins
This article was originally published in Scrip
As the third week of the full-year 2012 financial blizzard of reports brought the main part of earnings season to a stateside snowbound close, the take-home message of a difficult financial 2013 softened by spin-offs and other transactions meant that there will always be at least one winner, even if it is not an investor.
You may also be interested in...
Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.
With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?
The use of antibodies in disease prevention and treatment is now ingrained in modern medicine but as antiviral agents their record is at best patchy and the reliance on them to treat or prevent coronavirus infections is perhaps premature.